Innovation has been a hallmark of biotechnology for decades and, despite some of the hardest sledding in many years, 2024 could be a bounce-back year for biotech stocks.
The sector has suffered in this cycle. Investors have “rewarded” tech stocks and large-cap stocks for innovation, ignoring mid- and small-cap biotech stocks. Somehow, investors forgot about just how favorable the backdrop is for biotech, especially if AI is as big of a game changer as promised.
This post appeared first on InvestorPlace.